Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CC-90009 + Gilteritinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CC-90009||CC 90009||CC-90009 binds to the ubiquitin E3 ligase complex member cereblon (CRBN), which may lead to increased ubiquitination and proteosomal degradation of substrate proteins, including proteins involved in immune system activity or cell proliferation (NCI Drug Dictionary).|
|Gilteritinib||Xospata||ASP2215||AXL Inhibitor 27 FLT3 Inhibitor 54||Xospata (gilteritinib) is a small molecule inhibitor of FLT3 and AXL that has activity against FLT3-ITD, FLT3 F691L, and FLT3 D835 mutations, potentially resulting in decreased tumor growth (J Clin Oncol 32:5s, 2014 (suppl; abstr 7070), PMID: 25891481). Xospata (gilteritinib) is FDA approved for use in patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation (ITD, D835X, and I836X) (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04336982||Phase Ib/II||Azacitidine + CC-90009 + Venetoclax CC-90009 + Gilteritinib||A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia||Not yet recruiting|